Event Future event

ACCESS CHINA Biotech Forum @ JPM WEEK 2022

We cordially invite you to join our “ACCESS CHINA Biotech Forum @JPM Week 2022 to be held online from January 4thto 13th, 2022. As the largest CHINA corporate access event during the JPM WEEK in 2022, the forum expects to have over 1000 participants from China pharma and Biotech companies. The two-week event is divided into the following sessions:

  • Keynote Speeches
  • China Innovation Day
  • China Biotech Presentations
  • Global Biotech Roadshows
  • South Korea Biotech Presentations
  • YAFO East-Meet-West Dinner in SF

Witness the Emergence of China Biotech Innovation

As of November 5th, in 2021 there has been 29 China Out-licensing and 93 in-licensing transactions have been successfully closed, representing a 20+% YOY growth. It is a symbol of the rise of China biotech innovation as a result of China’s massive investment and favorable regulatory changes. As a facilitator between China biotech innovation and the rest of the world, our forum plans to present 50+ China and 50+ global biotech companies who are looking for partnering opportunities.

Examples of 2020 Presenting Companies Transactions

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.

We look forward to welcoming you at our winter showcase in January!

Two-Week  ACCESS  CHINA  Biotech Forum Agenda

Note: The updated one would be shown at https://biotochina.org/agenda/

We welcome the following global pharma and biotech to showcase:

Global pharma & biotech companies:

  • Looking for out-/in-licensing opportunities in China
  • With clinical-stage pharmaceutical assets
  • Focusing on Oncology, CNS, Cardiovascular, Ophthalmology, Orthopedics, Pediatrics, GI, and other therapeutic areas

Who are the attendees?

  • 50% are Chinese pharma/biotechs looking for in-licensing opportunities to enrich pipeline
  • 25% are Pharma/biotechsoutside China looking for in-licensing opportunities to enrich pipeline in China and other regions
  • 15% are VCs and PEs looking for pharma/biotech investment opportunities